# A comprehensive narrative review on the significance of hyaluronic acid for dental implantology

**Authors:** Ahmed Yaseen Alqutaibi, Nazrah Maher, Anum Mahmood, Faiza Amin, Ghulam Irtiza Mustafa, Naresh Kumar, Muhammad Sohail Zafar

PMC · DOI: 10.2340/biid.v13.45432 · Biomaterial Investigations in Dentistry · 2026-02-27

## TL;DR

This paper reviews how hyaluronic acid can improve dental implants by aiding healing and reducing inflammation.

## Contribution

The paper provides a comprehensive review of hyaluronic acid's role in enhancing dental implant success and tissue integration.

## Key findings

- Hyaluronic acid promotes wound healing and reduces inflammation around dental implants.
- HA coatings improve implant biocompatibility and peri-implant tissue healing.
- HA supports alveolar bone regeneration and osseointegration.

## Abstract

Dental implants have significantly advanced the scope of oral health care and practices, providing a stable and durable solution for replacing missing teeth. Essential maintenance practices, including regular oral hygiene and professional monitoring, are imperative to prevent complications such as peri-implant diseases, which can compromise implant integrity. Supplementary agents, including hyaluronic acid (HA), have been shown to enhance healing and integration. HA is recognised for its moisture-retaining properties, its promotion of wound healing, its reduction of inflammation, and its facilitation of tissue integration. The extensive therapeutic applications of HA in dental implant therapy are due to its biocompatibility and regulatory influences on cellular behaviour, which render HA a valuable adjunct to implant success, particularly concerning soft and hard tissue integration around the implants.

The present study aims to explore the potential applications of HA in dental implantology, including the modification of implant surfaces, the promotion of soft tissue healing around the implants, and the management of peri-implant diseases, such as mucositis and peri-implantitis. In addition, this study explores the role of HA in alveolar bone regeneration, particularly through alveolar ridge augmentation and preservation processes, as well as more advanced techniques such as tissue engineering, as the primary requirement for successful implant placement is sufficient bone width and depth. HA promotes osseointegration, increases osteogenesis, and helps treat peri-implant conditions such as mucositis and peri-implantitis. Implant biocompatibility, hydrophilicity, and bacterial adhesion resistance are all enhanced by HA coatings, which facilitate improved peri-implant bone and soft tissue healing. Stability and healing properties of HA can be increased by combining it with other biomaterials. Future studies should focus on enhancing HA’s mechanical properties, improving long-term bioactivity, and investigating synergistic biomaterial combinations; clinical trials are required to fully understand its potential in implant dentistry.

GRAPHICAL ABSTRACT

GRAPHICAL ABSTRACT

## Linked entities

- **Diseases:** mucositis (MONDO:0020579)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, HMMR (hyaluronan mediated motility receptor) [NCBI Gene 3161] {aka CD168, IHABP, RHAMM}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, mucin [NCBI Gene 100508689], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Bmp7 (bone morphogenetic protein 7) [NCBI Gene 85272] {aka BMP-7}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}
- **Diseases:** livedo reticularis (MESH:D054068), osteoporosis (MESH:D010024), ARP (MESH:D016301), joint diseases (MESH:D007592), cytotoxicity (MESH:D064420), gingivitis (MESH:D005891), urinary tract infections (MESH:D014552), dry eye (MESH:D015352), bone loss (MESH:D001847), sarcoidosis (MESH:D012507), infection (MESH:D007239), facial oedema (MESH:C536897), atrophic mandible (MESH:C563485), blisters (MESH:D001768), embolia cutis (MESH:D065148), orofacial granulomatosis (MESH:D051261), bony defect (MESH:D018213), necrosis (MESH:D009336), periodontal diseases (MESH:D010510), erythema (MESH:D004890), allergic reactions (MESH:D004342), granuloma (MESH:D006099), erysipelas (MESH:D004886), tenderness (MESH:D063806), contact dermatitis (MESH:D003877), mucositis (MESH:D052016), endocarditis (MESH:D004696), HA (MESH:D011015), Foreign body granuloma (MESH:D015745), resorption (MESH:D014091), Peri-implantitis (MESH:D057873), cataract (MESH:D002386), edema (MESH:D004487), Plaque (MESH:D003773), diabetes (MESH:D003920), vascular lesions (MESH:D014652), trismus (MESH:D014313), Skin necrosis (MESH:D012871), gingival recession (MESH:D005889), PD (MESH:D007222), pain (MESH:D010146), tooth loss (MESH:D016388), Complications (MESH:D008107), ear infections (MESH:D010031), inflammation (MESH:D007249), respiratory tract (upper) infections (MESH:D012141), CAL (MESH:D017622), ischemia (MESH:D007511), HA vascular complications (MESH:D003925), mPCL (MESH:D000069279), BOP (MESH:D006470)
- **Chemicals:** Se (MESH:D012643), N-acetyl-D-glucosamine (MESH:D000117), prostaglandin E1 (MESH:D000527), hydroxyapatite (MESH:D017886), Ti6Al4V (MESH:C031462), polycaprolactone (MESH:C016240), amino acid (MESH:D000596), titanium (MESH:D014025), nitroglycerin (MESH:D005996), dexamethasone (MESH:D003907), SYTO-9 (MESH:C103389), D-glucuronic acid (MESH:D020723), tacrolimus (MESH:D016559), glycosaminoglycan (MESH:D006025), BBSs (-), Calcium (MESH:D002118), imiquimod (MESH:D000077271), heparin (MESH:D006493), spermidine (MESH:D013095), lysine (MESH:D008239), minocycline (MESH:D008911), PLA (MESH:C033616), steroids (MESH:D013256), BP (MESH:C038809), polyamines (MESH:D011073), PEEK (MESH:C063834), polymers (MESH:D011108), uronic acid (MESH:D014574), polysaccharide (MESH:D011134), oxygen (MESH:D010100), allopurinol (MESH:D000493), sodium alginate (MESH:D000464), chitosan (MESH:D048271), sugars (MESH:D000073893), acid (MESH:D000143), chondroitin-6-sulfate (MESH:D002809), proline (MESH:D011392), calcium carbonates (MESH:D002119), HA (MESH:D006820), Glycine (MESH:D005998), cholesterol (MESH:D002784), methicillin (MESH:D008712), chlorhexidine (MESH:D002710), Oxysterol (MESH:D000072376), Ag (MESH:D012834), calcium phosphate (MESH:C020243), CS (MESH:D002133), retinoids (MESH:D012176), betatricalcium phosphate (MESH:C485817), water (MESH:D014867), leucine (MESH:D007930), tricalcium phosphates (MESH:C018392)
- **Species:** Homo sapiens (human, species) [taxon 9606], Staphylococcus epidermidis (species) [taxon 1282], Ralstonia (genus) [taxon 48736], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus aureus (species) [taxon 1280], Rattus norvegicus (brown rat, species) [taxon 10116], Rothia (genus) [taxon 508215], Streptococcus (genus) [taxon 1301], Hepatovirus A (no rank) [taxon 12092], Bos taurus (bovine, species) [taxon 9913], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090], Prevotella (genus) [taxon 838], Escherichia coli (E. coli, species) [taxon 562], Campylobacter (genus) [taxon 194], Sphingomonas (genus) [taxon 13687], Veillonella (genus) [taxon 29465]
- **Cell lines:** HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), NIH-3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), MG-63 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0426)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12954478/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12954478/full.md

## References

168 references — full list in the complete paper: https://tomesphere.com/paper/PMC12954478/full.md

---
Source: https://tomesphere.com/paper/PMC12954478